271 related articles for article (PubMed ID: 11108431)
1. Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Innocenti F; Iyer L; Ratain MJ
Clin Pharmacokinet; 2000 Nov; 39(5):315-25. PubMed ID: 11108431
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
Innocenti F; Iyer L; Ratain MJ
Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):596-600. PubMed ID: 11259359
[TBL] [Abstract][Full Text] [Related]
3. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.
Iyer L
Mol Diagn; 1999 Dec; 4(4):327-33. PubMed ID: 10671643
[TBL] [Abstract][Full Text] [Related]
4. Cancer pharmacogenomics: current and future applications.
Watters JW; McLeod HL
Biochim Biophys Acta; 2003 Mar; 1603(2):99-111. PubMed ID: 12618310
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
Quaranta S; Thomas F
Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261
[TBL] [Abstract][Full Text] [Related]
6. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.
Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A
Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
8. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Maitland ML; Vasisht K; Ratain MJ
Trends Pharmacol Sci; 2006 Aug; 27(8):432-7. PubMed ID: 16815558
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
10. Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk.
Lankisch TO; Schulz C; Zwingers T; Erichsen TJ; Manns MP; Heinemann V; Strassburg CP
Cancer Epidemiol Biomarkers Prev; 2008 Mar; 17(3):695-701. PubMed ID: 18349289
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetic influences on treatment response and toxicity in colorectal cancer.
Tan BR; McLeod HL
Semin Oncol; 2005 Feb; 32(1):113-9. PubMed ID: 15726513
[TBL] [Abstract][Full Text] [Related]
12. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
Mattison LK; Soong R; Diasio RB
Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping.
Innocenti F; Ratain MJ
Pharmacogenomics; 2006 Dec; 7(8):1211-21. PubMed ID: 17184208
[TBL] [Abstract][Full Text] [Related]
14. Individualization of thiopurine therapy: thiopurine S-methyltransferase and beyond.
Karas-Kuzelicki N; Mlinaric-Rascan I
Pharmacogenomics; 2009 Aug; 10(8):1309-22. PubMed ID: 19663675
[TBL] [Abstract][Full Text] [Related]
15. [Prediction of adverse drug reactions based on genomic information].
Sawada J; Saito Y
Nihon Rinsho; 2007 Oct; 65 Suppl 8():16-21. PubMed ID: 18074510
[No Abstract] [Full Text] [Related]
16. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
17. Uridine diphosphoglucuronosyl transferase and methylenetetrahydrofolate reductase polymorphisms as genomic predictors of toxicity and response to irinotecan-, antifolate- and fluoropyrimidine-based chemotherapy.
Toffoli G; Cecchin E
J Chemother; 2004 Nov; 16 Suppl 4():31-5. PubMed ID: 15688606
[TBL] [Abstract][Full Text] [Related]
18. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
Iyer L; Hall D; Das S; Mortell MA; Ramírez J; Kim S; Di Rienzo A; Ratain MJ
Clin Pharmacol Ther; 1999 May; 65(5):576-82. PubMed ID: 10340924
[TBL] [Abstract][Full Text] [Related]
19. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
Innocenti F; Ratain MJ
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):52-5. PubMed ID: 12800608
[TBL] [Abstract][Full Text] [Related]
20. [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Laurent-Puig P; Lièvre A; Ducreux M; Loriot MA
Bull Cancer; 2008 Oct; 95(10):935-42. PubMed ID: 19004723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
